SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
SEC Accession No. 0001193125-21-048255
Filing Date
2021-02-19
Accepted
2021-02-19 06:03:32
Documents
5

Document Format Files

Seq Description Document Type Size
1 DEFM14A d38874ddefm14a.htm DEFM14A 2193791
2 GRAPHIC g38874g10a22.jpg GRAPHIC 22076
3 GRAPHIC g38874g21k25.jpg GRAPHIC 24218
4 GRAPHIC g38874g27o56.jpg GRAPHIC 34354
5 GRAPHIC g38874g68r50.jpg GRAPHIC 47663
  Complete submission text file 0001193125-21-048255.txt   2363114
Mailing Address 5281 CALIFORNIA AVENUE SUITE 100 IRVINE CA 92617
Business Address 5281 CALIFORNIA AVENUE SUITE 100 IRVINE CA 92617 949-226-6029
Urovant Sciences Ltd. (Filer) CIK: 0001740547 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: DEFM14A | Act: 34 | File No.: 001-38667 | Film No.: 21651931
SIC: 2834 Pharmaceutical Preparations